Varian said it is investing in privately held Oncora Medical and will partner with the software company to develop machine learning-guided decision support tools. The aim is to help doctors create personalized treatment plans for cancer patients. Financial terms weren’t disclosed.
Philadelphia-based Oncora has developed an analytics platform in collaboration with MD Anderson oncologists that collects data on cancer patients, their treatments and clinical outcomes. The information is then used to model outcomes for treatments devised for new patients. Varian and Oncora plan to apply Oncora’s predictive models to help plan treatments that minimize the risk of toxicity to patients and improve the chances for a cure, Varian said.